lactose
Lactose is the most important carbohydrate in the milk of most species. Its biosynthesis takes place in the mammary gland. The molecular structures of α- and β -lactose differ in the orientation of a hydrogen- and a hydroxyl group on carbon atom no.1 in the glucose moiety. Both forms change into one another continuously. At room temperature, the equilibrium results in a ratio of about 40% α-lactose and 60% β-lactose. The fact that two forms of lactose exist which differ in molecular structure has profound effects on various properties of lactose such as crystallization behavior, crystal morphology, solid-state properties, and solubility. The intestine does not actively absorb lactose unless it is split into its two-monosaccharide components, i.e. glucose and galactose. This hydrolysis of lactose is affected by the enzyme lactase, which is produced by the epithelium cells in the brush-border of the small intestine. Thus, the capacity of mammals to digest lactose is dependent on the lactase activity in the intestine. The maximum activity of the enzyme occurs shortly after birth and declines during the weaning period, after which it remains at a relatively constant level. Genetically determined factors governing residual lactase activity also exist. Individuals having low lactase activity are called lactose malabsorbers. Lactose intolerance is a condition in which people have symptoms due to the decreased ability to digest lactose. The principal symptom of lactose intolerance is an adverse reaction to products containing lactose (primarily milk), including abdominal bloating and cramps, flatulence, diarrhea, nausea, borborygmi, and vomiting (particularly in adolescents). These appear one-half to two hours after consumption. — NCATS
Clinical trial activity
90 trials · 124 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 1994 (NCT00002620)
Timeline
Indications
Approved for
Studied for
- Acute Lung Injury · Phase 2
- Aging · Phase 3
- Airway Management · Phase 2
- Alcoholism · Phase 2
- Anxiety · Phase 2
- Asthma · Phase 3
- Attention Deficit Disorder with Hyperactivity · Phase 2
- Borderline Personality Disorder · Phase 2
- Brain Neoplasms · Phase 3
- Breast Neoplasms · Phase 3
- Bronchiectasis · Phase 1
- Chronic Periodontitis · Early Phase 1
- Cigarette Smoking · Phase 1
- Clinical Trial · Phase 4
- Cocaine-Related Disorders · Phase 2
- COVID-19 · Phase 3
- Cytomegalovirus Infections · Phase 2/Phase 3
- Depression · Phase 3
- Diabetes Mellitus, Type 2 · Phase 3
- Diabetic Retinopathy · Phase 2
- Diarrhea · Phase 3
- Endodontics · Phase 2
- Endometrial Neoplasms · Phase 3
- Esophageal Neoplasms · Phase 3
- Fatigue Syndrome, Chronic · Phase 2
- Fractures, Bone · Phase 4
- Gastroesophageal Reflux · Phase 2
- Head and Neck Neoplasms · Phase 3
- Healthy Volunteers · Phase 3
- Hepatic Encephalopathy · Phase 4
- Hepatitis A · Phase 2/Phase 3
- Hepatitis B · Phase 2/Phase 3
- Hepatitis C, Chronic · Phase 2/Phase 3
- Hyperalgesia · Phase 1
- Hyperkalemia · Phase 4
- Inflammation · Phase 2
- Influenza, Human · Phase 2
- Irritable Bowel Syndrome · Phase 2/Phase 3
- Kidney Failure, Chronic · Phase 4
- Lactose Intolerance · Phase 4
- Liver Diseases · Phase 2/Phase 3
- Lung Neoplasms · Phase 3
- Lupus Erythematosus, Systemic · Phase 2/Phase 3
- Macular Edema · Phase 2
- Metabolism · Phase 2
- Migraine Disorders · Phase 2
- Myocardial Ischemia · Phase 2
- Narcotics · Phase 2
- Nausea · Phase 2
- Neuralgia · Phase 3
- Nocturnal Enuresis · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 3
- Opioid-Related Disorders · Phase 2
- Ovarian Neoplasms · Phase 3
- Oxidative Stress · Phase 2
- Pain · Phase 2
- Paramyxoviridae Infections · Phase 2
- Pharmacokinetics · Phase 1
- Postoperative Pain · Phase 3
- Psychotic Disorders · Phase 4
- Pulmonary Disease, Chronic Obstructive · Phase 4
- Raynaud Disease · Phase 3
- Respiratory Distress Syndrome · Phase 2
- Rhinitis, Allergic, Seasonal · Phase 4
- Sarcopenia · Phase 4
- Schizophrenia · Phase 4
- Stress Disorders, Post-Traumatic · Phase 2
- Substance Withdrawal Syndrome · Phase 2
- Tinnitus · Phase 4
- Tuberculosis · Phase 3
- Urinary Tract Infections · Phase 4
- Uterine Cervical Neoplasms · Phase 3
- Vascular Stiffness · Phase 3
- Vitamin D Deficiency · Phase 3
- Vomiting · Phase 2
Mechanism of action
- D-lactoseSupplementation
D-lactose supplementation
Chemistry & pharmacology
SMILES
OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O- Mol. weight
- 342.3 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL417016 ↗
- WikipediaLactol ↗
- NCATS3SY5LH9PMK ↗
- ChEMBLCHEMBL5498481 ↗
- WikipediaLactose ↗
- ChEMBLCHEMBL2104612 ↗
- ChEMBLCHEMBL5314358 ↗
- ChEMBLCHEMBL2106323 ↗
Also known as
- aletobiose
- anhydrous lactose
- anhydrous lactose
- anhydrous lactose
- anhydrous lactose
- anhydrous lactose
- dibromdulcit
- dibromodulcitol
- dibromodulcitol
- dibromodulcitol
- dibromodulcitol
- dibromogalactitol
- dilactose
- elobromol
- lactobiose
- lactol
- lactol
- lactose
- lactose
- lactose
- lactose
- lactose
- lactose
- lactose
- lactose
- (+)-lactose
- lactose, anhydrous
- lactose, anhydrous
- lactose monohydrate
- lactose monohydrate
- lactose monohydrate
- mitolactol
- mitolactol
- mitolactol
- mitolactol
- mitolactol
- mitolactol
- respitose
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06724705 | N/A | Dec 5, 2024 | University of Maryland |
| NCT06177938 | N/A | Dec 31, 2023 | Agroscope Liebefeld-Posieux Research Station ALP, University of Zurich |
| NCT05416229 | Phase 2 | Oct 31, 2022 | University of Copenhagen |
| NCT06618573 | Phase 2/Phase 3 (Phase 3) | Aug 15, 2022 | Padjadjaran University |
| NCT05245175 | N/A | Feb 22, 2022 | Fraunhofer, University of California, Irvine |
| NCT05712616 | Phase 4 | Nov 1, 2021 | Aga Khan University |
| NCT04924530 | N/A | Jun 7, 2021 | British Heart Foundation, University of Bath, University of Oxford |
| NCT04894617 | Phase 3 | Jun 1, 2021 | University of Copenhagen |
| NCT04791943 | Phase 2 | May 12, 2021 | Yeshiva University |
| NCT04481971 | Phase 2 | Aug 9, 2020 | King Saud University |
| NCT04237090 | Phase 3 | Feb 29, 2020 | Ciusss de L'Est de l'Île de Montréal |
| NCT04100109 | N/A | Nov 1, 2019 | University of Minnesota |
| NCT04450134 | N/A | Oct 2, 2019 | Ghent University, Government of Belgium, University of Copenhagen |
| NCT03497598 | Phase 4 | May 9, 2018 | Kantonsspital Aarau |
| NCT03476447 | N/A | Apr 6, 2018 | Evolve Biosystems, Inc., University of California, Davis |
| NCT02999022 | Phase 2 | Apr 17, 2017 | Canadian Institutes of Health Research (CIHR), University of Toronto |
| NCT03161652 | Phase 2 | May 1, 2016 | Instituto Mexicano de Oftalmologia, National Autonomous University of Mexico, Paracelsus Medical University, Universidad Autonoma de Queretaro, Universidad Nacional Autonoma de Mexico |
| NCT04389931 | N/A | Mar 31, 2016 | Universidad Nacional Andres Bello |
| NCT03670212 | Phase 1 | Jan 7, 2016 | National Institute on Drug Abuse (NIDA), Wayne State University |
| NCT02566798 | N/A | Dec 1, 2015 | University of Nantes |